Large study aims to uncover best treatments for lymphoma patients with dangerous immune reaction

NCT ID NCT05898477

Recruiting now Knowledge-focused Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is observing 2,000 lymphoma patients who also develop hemophagocytic lymphohistiocytosis (HLH), a severe immune overreaction. Researchers will collect data on which treatments patients receive and how they respond, aiming to identify factors that improve survival at 180 days. The goal is to find better therapeutic strategies for this high-risk group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could identify better treatment strategies for lymphoma patients who develop HLH, potentially improving survival rates.
What could go wrong: This is an observational study, not a treatment trial. It will not test new therapies directly, and results may not lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hemophagocytic syndrome Lymphohistiocytosis, Hemophagocytic lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSES LYMPHOMA

Contacts and locations

Locations

University of Alabama at Birmingham
RECRUITING

Birmingham, Alabama, 35294, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.